Alumis Inc (NASDAQ:ALMS) — Market Cap & Net Worth
Market Cap & Net Worth: Alumis Inc (ALMS)
Alumis Inc (NASDAQ:ALMS) has a market capitalization of $2.83 Billion ($2.83 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5194 globally and #1691 in its home market, demonstrating a 20.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alumis Inc's stock price $23.00 by its total outstanding shares 123139425 (123.14 Million). Review total liabilities of Alumis Inc to assess the company's total debt and financial obligations.
Alumis Inc Market Cap History: 2024 to 2026
Alumis Inc's market capitalization history from 2024 to 2026. Data shows growth from $967.88 Million to $2.83 Billion (20.26% CAGR).
Index Memberships
Alumis Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.12% | #123 of 976 |
|
NASDAQ Composite
IXIC
|
$41.39 Trillion | 0.01% | #579 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.17% | #77 of 263 |
Weight: Alumis Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alumis Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alumis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
49.97x
Alumis Inc's market cap is 49.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $1.20 Billion | $24.05 Million | -$243.32 Million | 49.97x | N/A |
Competitor Companies of ALMS by Market Capitalization
Companies near Alumis Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Alumis Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Alumis Inc Historical Marketcap From 2024 to 2026
Between 2024 and today, Alumis Inc's market cap moved from $967.88 Million to $ 2.83 Billion, with a yearly change of 20.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.83 Billion | +135.66% |
| 2025 | $1.20 Billion | +24.17% |
| 2024 | $967.88 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Alumis Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.83 Billion USD |
| MoneyControl | $2.83 Billion USD |
| MarketWatch | $2.83 Billion USD |
| marketcap.company | $2.83 Billion USD |
| Reuters | $2.83 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment o… Read more